Serina Therapeutics, Inc. (SER) has entered into definitive agreements for a private placement of common stock and pre-funded warrants, raising up to $30 million to support its registrational trial of SER-252 in advanced Parkinson's disease.
The first $15 million tranche is expected to close on March 20, 2026, with a second tranche of up to $15 million anticipated by April 30, 2026.
The financing includes 50% warrant coverage priced at $5 per share, representing a significant premium to market. If fully exercised, the warrants could provide an additional $33.3 million, extending Serina's cash runway into the second half of 2027. The transaction is led by board director Greg Bailey, M.D., who will assume the role of Co-Chairman alongside Simba Gill, Ph.D.
Proceeds will fund the ongoing single-ascending dose registrational study of SER-252, which is being advanced under a 505(b)(2) NDA pathway. SER-252, developed using Serina's proprietary POZ platform, is designed to provide continuous dopaminergic stimulation, potentially reducing motor complications in patients whose symptoms are inadequately controlled by current therapies.
Management emphasized that with the first patient already dosed and FDA feedback confirming a clear regulatory pathway, the financing positions Serina to deliver on key milestones.
SER has traded between $1.22 and $7.92 over the past year. The stock closed Wednesday's trading at $1.28, down 4.48%. During the overnight session the stock rose to $1.64, up 28.13%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.